2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. PARP

PARP

poly ADP ribose polymerase

PARP

Related Products

PDF 1.49 MB

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Isoform Specific Products:

PARP Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-151625
    PARP-2-IN-3
    		Inhibitor
    PARP-2-IN-3 (Compound 12) is a potent PARP-2 inhibitor with an IC50 of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability.
    PARP-2-IN-3
  • HY-RS10068
    Parp4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Parp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Parp4 Rat Pre-designed siRNA Set A
    Parp4 Rat Pre-designed siRNA Set A
  • HY-153259
    TNKS1/2-IN-2
    		Inhibitor
    TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC50 values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC50 values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer.
    TNKS1/2-IN-2
  • HY-RS10055
    PARP14 Human Pre-designed siRNA Set A
    		Inhibitor

    PARP14 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PARP14 Human Pre-designed siRNA Set A
    PARP14 Human Pre-designed siRNA Set A
  • HY-155570
    Anticancer agent 137
    		Inducer
    Anticancer agent 137 (8q) is a potent PI3k inhibitor. Anticancer agent 137 has broad-spectrum anticancer activity. Anticancer agent 137 induces G2/M cell cycle arrest and apoptosis. Anticancer agent 137 increases cleaved PARP, caspase 3, and 7. Anticancer agent 137 can be used in research of cancer.
    Anticancer agent 137
  • HY-164926
    PARP1-IN-33
    		Inhibitor 99.87%
    PARP1-IN-33 (Example 6) is a PARP1 inhibitor (IC50: 0.41 nM). PARP1-IN-33 has retinal cytoprotective effect, with an EC50 of 0.02 nM (inhibition on MTS activity of H2O2 induced human retinal pigment epithelial cell).
    PARP1-IN-33
  • HY-RS10067
    Parp4 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Parp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Parp4 Mouse Pre-designed siRNA Set A
    Parp4 Mouse Pre-designed siRNA Set A
  • HY-145266
    OM-1700
    		Inhibitor
    OM-1700 is a potent tankyrase inhibitor with IC50s of 127 and 14 nM for tankyrase 1 and tankyrase 2, respectively. OM-1700 reduces cell growth in the colon cancer cell line COLO 320DM (GI50=650 nM).
    OM-1700
  • HY-169299
    TOPOI/PARP-1-IN-2
    		Inhibitor
    TOPOI/PARP-1-IN-2 (compound 6c) is a dual PARP-1 and topoisomerase 1 (TOPO-1) inhibitor with IC50s of 32.2 nM and 46.2 nM, respectively. TOPOI/PARP-1-IN-2 shows a selectivity for PARP-1 over PARP-2. TOPOI/PARP-1-IN-2 disrupts the cell cycle at the S phase and induces apoptosis in NCI-60 cancer cell lines.
    TOPOI/PARP-1-IN-2
  • HY-162644
    Antitumor agent-170
    		Inhibitor
    Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics.
    Antitumor agent-170
  • HY-B1899R
    Taurodeoxycholic acid (Standard)
    		Activator
    Taurodeoxycholic acid (Standard) is the analytical standard of Taurodeoxycholic acid. This product is intended for research and analytical applications. Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholic acid is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholic acid is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholic acid (TDCA) exhibits anti-inflammatory and neuroprotective effects[1][2][3][9][10].
    Taurodeoxycholic acid (Standard)
  • HY-155246
    PARP1-IN-15
    		Inhibitor
    PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations.
    PARP1-IN-15
  • HY-RS14546
    TIPARP Human Pre-designed siRNA Set A
    		Inhibitor

    TIPARP Human Pre-designed siRNA Set A contains three designed siRNAs for TIPARP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    TIPARP Human Pre-designed siRNA Set A
    TIPARP Human Pre-designed siRNA Set A
  • HY-169336
    CQ-16
    		Inhibitor
    CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
    CQ-16
  • HY-168877
    FMP
    		Activator
    FMP is a Platinum(IV) complexe. FMP significantly upregulates the expression of γ-H2AX and p53. FMP increases the production of ROS. FMP markedly upregulates the expressions of Apoptosis-related proteins (DR5, Fas, caspase-8, Cyt-c, caspase-3, cleaved-PARP1, Bax). FMP shows antiproliferative activity against breast cancer.
    FMP
  • HY-148709
    ARTD10/PARP10-IN-1
    		Inhibitor
    ARTD10/PARP10-IN-1 (compound 23) is a potent and non-selective PARP inhibitor, targeting to mono-ADP-ribosyltransferases ARTD7/PARP15, ARTD8/PARP14, ARTD10/PARP10 and poly(ADP-ribose) polymerase-1 (ARTD1/PARP1) with IC50s of 1.7 μM, 1.6 μM, 0.8 μM, and 4.4 μM, respectively.
    ARTD10/PARP10-IN-1
  • HY-173597
    ZINC43120769
    		Inhibitor
    ZINC43120769 is a PARP1 inhibitor. ZINC43120769 can be used in prostate cancer (PC) research.
    ZINC43120769
  • HY-RS10051
    Parp10 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Parp10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Parp10 Mouse Pre-designed siRNA Set A
    Parp10 Mouse Pre-designed siRNA Set A
  • HY-15048
    GPI 15427
    		Inhibitor
    GPI 15427 is a potent inhibitor of the enzyme poly (ADP-ribose) polymerase-1 (PARP-1), which plays a harmful role during inflammation. In a rat model of gut injury and inflammation, including splanchnic artery occlusion (SAO) shock and dinitrobenzene sulfonic acid (DNBS)-induced colitis, GPI 15427 demonstrated strong anti-inflammatory effects. It reduced inflammatory cell infiltration, histological injury, and delayed clinical signs of inflammation. GPI 15427 also diminished the accumulation of poly (ADP-ribose) in the ileum and colon of treated rats. These results suggest GPI 15427 could be useful for treating intestinal ischemia and inflammation.
    GPI 15427
  • HY-155122
    PARP-1-IN-13
    		Inhibitor
    PARP-1-IN-13 (Compound 19c) is a PARP-1 inhibitor (IC50: 26 nM). PARP-1-IN-13 inhibits DNA single-strand breakage repair and aggravates DNA double-strand breakage. PARP-1-IN-13 promotes the apoptosis of cancer cells through the mitochondrial apoptosis pathway.
    PARP-1-IN-13
Cat. No. Product Name / Synonyms Application Reactivity
PARP Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.